Copyright
©The Author(s) 2016.
World J Gastroenterol. Nov 21, 2016; 22(43): 9613-9622
Published online Nov 21, 2016. doi: 10.3748/wjg.v22.i43.9613
Published online Nov 21, 2016. doi: 10.3748/wjg.v22.i43.9613
Table 2 Sustained virologic response by treatment modifications and hepatitis C virus genotype (n = 288) n (%)
| Achieved SVR | P value | ||
| Yes(n = 237) | No(n = 51) | ||
| Dose reduction | |||
| Any dose reduction | 43 (79.6) | 11 (20.4) | 0.570 |
| Peg-IFN only | 9 (100) | 0 (0) | 0.157 |
| Ribavirin only | 12 (70.6) | 5 (29.4) | 0.193 |
| Both peg-IFN and ribavirin | 22 (78.6) | 6 (21.4) | 0.587 |
| Genotype | |||
| 1 | 42 (75.0) | 14 (25.0) | 0.314 |
| 2 | 4 (100) | 0 (0) | |
| 3 | 123 (84.8) | 22 (15.2) | |
| 6 | 68 (81.9) | 15 (18.1) | |
- Citation: Hlaing NKT, Banerjee D, Mitrani R, Arker SH, Win KS, Tun NL, Thant Z, Win KM, Reddy KR. Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country. World J Gastroenterol 2016; 22(43): 9613-9622
- URL: https://www.wjgnet.com/1007-9327/full/v22/i43/9613.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i43.9613